See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $27.9B | 12.6x | -84.3x | |
| $21.2B | 6.6x | 44.5x | |
| $18.8B | 4.4x | 15.8x | |
| $14.4B | 14.8x | -67.8x | |
| $4.0B | 13.5x | 173.3x | |
| $3.4B | 23.2x | -8.8x | |
| $3.1B | 3.2x | 17.9x | |
| $2.9B | 7.5x | -74.8x | |
| $2.6B | 6.0x | 64.1x | |
| $2.5B | n/a | n/a | |
| $2.5B | 5.0x | 19.2x | |
| $1.9B | 3.1x | -36.3x | |
| $1.0B | 174.8x | -8.8x | |
| $963M | 1.6x | 13.5x | |
| $900M | 5.7x | -6.4x | |
| $843M | 2.3x | 22.4x | |
| $764M | 28.4x | -11.3x | |
| $725M | 2.2x | 20.0x | |
| $707M | 2.2x | 12.8x | |
| $684M | 27.8x | -10.8x | |
| $619M | 8.9x | -7.8x | |
| $512M | n/a | -4.0x | |
| $499M | 87.6x | -2.6x | |
| $485M | 0.6x | 15.7x | |
| $465M | 83.0x | n/a | |
| $362M | 1.1x | -63.5x | |
| $346M | 3.6x | n/a | |
| $345M | n/a | -3.1x | |
| $309M | 4.1x | -7.1x | |
| $309M | 4.0x | -6.6x | |
| $308M | n/a | n/a | |
| $293M | 0.7x | -9.4x | |
| $275M | n/a | -31.8x | |
| $262M | n/a | n/a | |
| $225M | 54.0x | -5.1x | |
| $214M | n/a | -1.2x | |
| $174M | 4.9x | -1.4x | |
| $142M | 39.0x | -2.6x | |
| $140M | 2.1x | -3.1x | |
| $93.2M | 37.8x | -4.1x | |
| $91.9M | n/a | -1.1x | |
| $88.5M | 15.3x | n/a | |
| $80.3M | 8.8x | -1.1x | |
| $65.6M | 0.6x | n/a | |
| $57.4M | 10.4x | n/a | |
| $42.4M | 0.9x | n/a | |
| $26.8M | 2.9x | -0.2x | |
| $22.9M | 1.0x | -0.1x | |
| $13.5M | n/a | n/a | |
| $7.7M | n/a | n/a | |
| $6.8M | 0.2x | n/a | |
| $5.5M | n/a | n/a | |
| $0.2M | n/a | n/a | |
| -$15.3M | n/a | n/a | |
| -$87.6M | -3.1x | 0.9x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine